Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H30N4O2S.ClH.2H2O |
Molecular Weight | 499.066 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.Cl.[H][C@@]12CCCC[C@]1([H])C(=O)N(CCCCN3CCN(CC3)C4=NSC5=C4C=CC=C5)C2=O
InChI
InChIKey=LZQKLGXZZSMREH-SMMZMSQNSA-N
InChI=1S/C23H30N4O2S.ClH.2H2O/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21;;;/h3-4,9-10,17-18H,1-2,5-8,11-16H2;1H;2*1H2/t17-,18+;;;
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C23H30N4O2S |
Molecular Weight | 426.575 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugbank.ca/drugs/DB08922Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/12054062
Sources: https://www.drugbank.ca/drugs/DB08922
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/12054062
Perospirone (Lullan®) is an atypical antipsychotic of the azapirone family. It is used in Japan for the treatment of schizophrenia and acute cases of bipolar mania. Its primary mode of action is through antagonism of serotonin 5-HT2A and dopamine D2 receptors.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12054062 |
0.6 nM [Kd] | ||
Target ID: CHEMBL219 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9577836 |
0.09 nM [Kd] | ||
Target ID: CHEMBL322 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12054062 |
1.3 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | LULLAN Approved UseFor the treatment of schizophrenia and acute cases of bipolar mania. Launch Date2000 |
|||
Sources: https://www.drugbank.ca/drugs/DB08922 |
Palliative | LULLAN Approved UseFor the treatment of schizophrenia and acute cases of bipolar mania. Launch Date2000 |
PubMed
Title | Date | PubMed |
---|---|---|
Brain receptors for antipsychotic drugs and dopamine: direct binding assays. | 1975 Nov |
|
Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. | 1992 Apr 10 |
|
Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. | 1998 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.pharmacodia.com/web/drug/1_13.html
The recommended dose is 4 mg three times daily taken after meals, and daily dose should not exceed 48 mg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1982326
The binding affinity of perospirone (SM-9018) for various neurotransmitter and drug-receptors was investigated in the rat brain. SM-9018 possessed very high affinity for 5-HT2, D2 and 5-HT1A receptors (Ki = 0.61, 1.4 and 2.9 nM, respectively), and it had moderate affinity for alpha 1 and D1 receptors (Ki = 17 and 41 nM, respectively). However, SM-9018 had only negligible affinity for alpha 2, opiate, glutamate, phencyclidine, benzodiazepine and GABA-A receptors.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:12:49 GMT 2023
by
admin
on
Fri Dec 15 19:12:49 GMT 2023
|
Record UNII |
S03S4466IP
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID70172763
Created by
admin on Fri Dec 15 19:12:49 GMT 2023 , Edited by admin on Fri Dec 15 19:12:49 GMT 2023
|
PRIMARY | |||
|
S03S4466IP
Created by
admin on Fri Dec 15 19:12:49 GMT 2023 , Edited by admin on Fri Dec 15 19:12:49 GMT 2023
|
PRIMARY | |||
|
192052-81-6
Created by
admin on Fri Dec 15 19:12:49 GMT 2023 , Edited by admin on Fri Dec 15 19:12:49 GMT 2023
|
PRIMARY | |||
|
5282504
Created by
admin on Fri Dec 15 19:12:49 GMT 2023 , Edited by admin on Fri Dec 15 19:12:49 GMT 2023
|
PRIMARY | |||
|
SUB16454MIG
Created by
admin on Fri Dec 15 19:12:49 GMT 2023 , Edited by admin on Fri Dec 15 19:12:49 GMT 2023
|
PRIMARY | |||
|
100000078586
Created by
admin on Fri Dec 15 19:12:49 GMT 2023 , Edited by admin on Fri Dec 15 19:12:49 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
||
|
ANHYDROUS->SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |